Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
OBJECTIVE
Exemestane (EXE) and letrozole (LET) are third-generation aromatase inhibitors currently prescribed for postmenopausal hormone-dependent breast cancer. The impact on end organs of estrogen depletion in menopausal women is of significant clinical importance. We studied the effects of EXE, its principal metabolite, 17-hydroexemestane (17-H-EXE), and LET on bone and lipid metabolism in ovariectomized (OVX) rats.


METHODS
OVX rats were treated by weekly intramuscular injection for 16 weeks with 20, 50, and 100 mg/kg EXE, 20 mg/kg 17-H-EXE, and daily oral gavage of 1 mg/kg LET. At the end of the treatment period, bone mineral density (BMD), the bone resorption marker serum pyridinoline, the bone formation marker serum osteocalcin, bone mechanical properties, histomorphometry, and serum lipid concentrations were determined.


RESULTS
Lumbar vertebral and femoral BMD, bending strength of the femur, compressive strength of the fifth lumbar vertebra, and trabecular bone volume were significantly higher in OVX animals given EXE and 17-H-EXE than in OVX controls. EXE and 17-H-EXE significantly reduced an ovariectomy-induced increase in serum pyridinoline and serum osteocalcin. EXE and 17-H-EXE given to OVX rats caused significant reductions of serum cholesterol and low-density lipoprotein cholesterol. In contrast, OVX rats treated with LET had BMD, bone biomarkers, mechanical failure properties, and lipid levels similar to those of OVX controls.


CONCLUSIONS
EXE and 17-H-EXE significantly prevent bone loss, enhance bone mechanical strength, and lower serum cholesterol and low-density lipoprotein levels in OVX rats. These protective effects on end-organ function are not seen with the nonsteroidal inhibitor LET.
Goss
Paul E
PE
Breast Cancer Prevention Program, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada. pegoss@interlog.com
Qi
Shangle
S
Cheung
Angela M
AM
Hu
Haiqing
H
Mendes
Maria
M
Pritzker
Kenneth P H
KP
D000596:Amino Acids / Q000097:blood; D000730:Androstadienes / Q000494:pharmacology*; D000818:Animals; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001842:Bone and Bones / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005269:Femur / Q000187:drug effects / Q000201:enzymology; D007273:Injections, Intramuscular; D000077289:Letrozole; D050356:Lipid Metabolism; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000201:enzymology; D009570:Nitriles / Q000494:pharmacology*; D015675:Osteocalcin / Q000097:blood; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013256:Steroids / Q000737:chemistry; D014230:Triazoles / Q000494:pharmacology*
D000596:Amino Acids; D000730:Androstadienes; D047072:Aromatase Inhibitors; D008078:Cholesterol, LDL; D009570:Nitriles; D013256:Steroids; D014230:Triazoles; D015675:Osteocalcin; C015484:pyridinoline; D000077289:Letrozole; D002784:Cholesterol; C056516:exemestane